CONTEXT: RWR shows reduced exacerbations, MG crises and hospitalisations in myasthenia Gravis patients (MG) who were on eculizumab (Soliris) in a real-world study presented at the virtual AAN annual meeting | US only data.
IMPACT: Medium
READ TIME: 3 mins
Quality Level Mean [1 – 10]: 7
1. “Regarding rescue therapy, 26 (32.1%) patients had been given intravenous immunoglobulin (IVIG) for MG exacerbations — a treatment that consists of immune proteins meant to quickly suppress the immune system — before Soliris.”
2. “Go here to read the latest stories from the conference. Soliris (eculizumab), a treatment for people with generalized myasthenia gravis (gMG) who fail to respond to other therapies, reduced exacerbations, MG crises, a hospitalization’s length, and the need for rescue therapy, according to data from a real-world U.S. study.”
3. “During the six months before starting treatment with Soliris, 38.3% of patients experienced MG exacerbations and 24.7% reported an MG crisis.”
4. “Likewise, 19 (23.5%) patients were given IVIG for an MG crisis before Soliris initiation, and one patient (1.3%) during treatment.”
5. “Plasma exchange (or plasmapheresis), a procedure in which a patient’s blood plasma is removed, and filtered of harmful antibodies before being returned, was conducted in 11 (13.6%) patients for exacerbations and in nine (11.1%) for MG crisis before Soliris.”